US Government Updates Guidelines to Reduce Veteran Suicide


A new set of 22 recommendations include a combination of universal screenings, medication, and other preventative initiatives in an effort to drive down veteran suicide rates.

Newly updated guidelines will provide health care providers with a framework to screen, evaluate, treat, and manage the needs and preferences of veterans at risk of suicide.

The US Department of Veterans Affairs (VA) and the US Department of Defense (DoD) Evidence-Based Practice Work Group approved an update to the 2013 joint clinical practice guideline that now includes a set of 22 recommendations aimed at preventing veteran suicide.

The guidelines include using a validated screening tool to identify individuals at risk for suicide-related behavior, an assessment of risk factors as part of a comprehensive evaluation of suicide risk, using cognitive behavioral therapy-based interventions focused on suicide prevention for patients with a recent history of self-directed violence, Dialectical Behavioral Therapy for individuals with borderline personality disorder, and completing a crisis response plan for individuals with suicidal ideation or a lifetime history of suicide attempts.

The investigators begin in January 2018, taking on a process that included drafting key questions, systematically searching and evaluating literature through April 2018, creating algorithms and advancing the 22 recommendations in accordance to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.

The risk management and treatment recommendations address both pharmacologic and nonpharmaologic approaches for patients with suicidal ideation and behavior. The team also used other management methods to address lethal means safety, such as restricting access to firearms, poisons and medications, and installing barriers to prevent jumping from lethal heights, as well as population health strategies.

Another recommendation calls for the use of lithium and clozapine.

“Lithium may reduce the risk for suicide in patients with unipolar depression or bipolar disorder,” the authors wrote. “Several cohort studies and systematic reviews found that lithium maintenance therapy was associated with fewer suicidal behaviors and death. Clozapine may reduce suicidal behaviors in patients with schizophrenia or schizoaffective disorder.”

Between 1999-2016 the nationwide suicide rate increased 25% with Nevada the only state to report a decrease in suicide rate. During the same time period, the DoD active component suicide rate increased from 10.7 to 21.5 suicide-related death per 100,000 service members.

In particular, suicide rates have been high among army personnel, the service members engaged in the most ground combat during recent conflicts in Iraq and Afghanistan.

“In 2016, suicide occurred in 26.7, 31.6, and 20.6 per 100,000 U.S. Army, Army National Guard, and Army Reserve members, respectively,” the authors wrote. “According to DoD Suicide Event Report data, 127 army soldiers and 150 national guard or reserve members took their own lives in 2016.”

According to the report, 20 veterans commit suicide daily, a 21% higher suicide rate than civilian cohorts when matched by age and sex.

There was also a difference within service member subsets that utilized Veterans Health Administration (VHA) services. There is an 8% increase in suicides in those who use VHA services, but a 35.5% increase in those who did not.

There is also an 81.6% increase in suicide rates among female veterans who do not use VHA services.

The study, “Assessment and Management of Patients at Risk for Suicide: Synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines,” was published online in the Annals of Internal Medicine.

Related Videos
HCPLive Five at APA 2024 | Image Credit: HCPLive
John M. Oldham, MD: A History of Personality Disorder Pathology
Franklin King, MD: Psychedelic Therapy History, Advances, and Hurdles
Robert Weinrieb, MD: Psychiatry-Hepatology Approach for Alcohol-Related Liver Disease
Etienne Sibille, PhD: Innovations in Cognitive Pathology
Katharine Phillips, MD: Various Treatments for Obsessive-Compulsive Disorders
Manish Jha, MD: Treatment Options for Treatment-Resistant Depression
Katharine Phillips, MD: Differences Between OCD, Body Dysmorphic Disorder
Brian Barnett, MD: Psychedelics Fitting into the SUDs Treatment Paradigm
© 2024 MJH Life Sciences

All rights reserved.